Peptides for chronic fatigue FAQ

Reassess whether immune dysregulation is the primary driver of your fatigue. Some CFS cases initially appear immune-dominant but are actually neurological or metabolic at the root. Elevated cytokines may be secondary to mitochondrial dysfunction or chronic stress signalling rather than primary immune failure. If Thymalin produces no cytokine normalisation after eight weeks at therapeutic dose, pivot to neuroprotective peptides like Cerebrolysin or metabolic peptides like MK-677. Continuing a non-responsive protocol beyond this window wastes time and delays identifying the correct mechanism.

This pattern suggests neurological recovery outpacing metabolic or mitochondrial repair. Add a growth hormone secretagogue (MK-677 or CJC-1295/Ipamorelin) to your existing neuroprotective peptide protocol. Cognitive function can improve through synaptic remodelling while cellular ATP production remains impaired. They operate on different timelines. Mitochondrial biogenesis takes 8–12 weeks, whereas synaptic plasticity changes occur within 4–6 weeks. The lag is expected and doesn't indicate protocol failure.

Start with comprehensive immune and metabolic panels before selecting a peptide protocol. Request cytokine profiling (IL-6, TNF-alpha, IL-1beta), lymphocyte subset analysis (CD4+/CD8+ ratios, NK cell activity), serum BDNF, and mitochondrial function markers (lactate-to-pyruvate ratio, ATP production in muscle biopsy if accessible). The testing cost ranges from $400–$1,200 depending on panel depth, but it prevents wasting months on peptides targeting the wrong pathway. Insurance rarely covers these as diagnostic tools for CFS, but functional medicine clinics and research-oriented physicians can order them.